Angiogenesis and liver fibrogenesis

Histology and Histopathology

Volumn 24, Issue 10, 2009, Pages 1323-1341

  di Bonzo, Lorenzo Valfrè ^a   Novo, Erica ^a   Cannito, Stefania ^a   Busletta, Chiara ^a   Paternostro, Claudia ^a   Povero, Davide ^a   Parola, Maurizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Hepatic myofibroblasts; Hepatic stellate cells; Liver angiogenesis; Pro angiogenic cytokines; VEGF

Indexed keywords

ANIMAL; ANOXIA; BLOOD VESSEL; EXPERIMENTAL LIVER CIRRHOSIS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANOXIA; BLOOD VESSELS; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER DISEASES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 75349088284     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K. and Cherrington J.M. (2003). SU11248 inhibits KIT and paltelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer. Ther. 2, 471-478.
2. Ahima R.S. and Osei S.Y. (2004). Leptin signaling. Physiol. Behav. 81. 223-241.
3. Aleffi S., Petrai I., Bertolani C., Parola M., Colombatto S., Novo E., Vizzutti F., Anania F.A., Milani S., Rombouts K., Laffi G., Pinzani M. and Marra F. (2005). Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 42, 1339-1348.
4. Angulo P. (2002). Non-alcoholic fatty liver disease. N. Engl. J. Med. 346, 1221-1231.
5. Ankoma-Sey V., Matli M., Chang K.B., Lalazar A., Donner D.B., Wong L., Warren R.S. and Friedman S.L. (1998). Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing. Oncogene 17, 115-121.
6. Ankoma-Sey V., Wang Y. and Dai Z. (2000). Hypoxic stimulation of vascular endothelial growthfactor expression in activated rat hepatic stellate cells. Hepatology 31, 141-148.
7. Armulik A., Abramsson A. and Betsholtz C. (2005). Endothelial/pericyte interactions. Circ. Res. 97, 512-523.
8. Arteel G.E., Thurman R.G., Yates J.M. and Raleigh J.A. (1995). Evidence that hypoxiamarkers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72, 889-895.
9. Arteel G.E., Imuro Y., Yin M., Raleigh J.A. and Thurman R.G. (1997). Chronic enteralethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 25, 920-926.
10. Bataller R. and Brenner D.A. (2005). Liver fibrosis. J. Clin. Invest. 115, 109-118.
11. Blomhoff R. and Wake K. (1991). Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J. 5, 271-277.
12. Bozova S. and Elpek G.O. (2007). Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS 115, 795-801.
13. Bussolino F., Di Renzo M.F., Ziche M., Bocchietto E., Olivero M., Naldini L., Gaudino G., Tamagnone L., Coffer A. and Comoglio P.M. (1992). Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119, 629-641.
14. Camenisch G., Pisabarro M.T., Sherman D., Kowalski J., Nagel M., Hass P., Xie M.H., Gurney A., Bodary S., Liang X.H., Clark K., Beresini M., Ferrara N. and Gerber H.P. (2002). ANGPTL3 stimulates endothelial cell adhesion and migration via integrin avß3 and induces blood vessel formation in vivo. J. Biol. Chem. 277, 17281-17290.
15. Carlson T.R., Feng Y., Maisonpierre P.C., Mrksich M. and Morla A.O. (2001) Direct cell adhesion to the angiopoietins mediated by integrins. J. Biol. Chem. 276, 26516-26525.
16. Carmeliet P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660.
17. Carmeliet P. (2004). Manipulating angiogenesis in medicine. J Intern. Med. 255, 538-561.
18. Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C., Poupon R., Housset C. and Rosmorduc O. (2002a). Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35, 1010-1021.
19. Corpechot C., Barbu V., Wendum D., Chignard N., Housset C., PouponR. and Rosmorduc O. (2002b). Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am. J. Pathol. 160, 613-620.
20. Deeks E.D. and Keating G.M. (2006). Sunitinib. Drugs 66, 2255-2266.
21. DeLeve L.D., Wang X., Hu L., McCuskey M.K. and McCuskey R.S. (2004). Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am. J. Physiol.-Gastrointest. Liver. Physiol. 287, G757-G763.
22. Dewhirst M.W., Cao Y. and Moeller B. (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Rev. Cancer 8, 424-438.
23. Faggioni R., Jones-Carson J., Reed D.A., Dinarello C.A., Feingold K.R., Grunfeld C. and Fantuzzi G. (2000). Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc. Natl. Acad. Sci. USA 97, 2367-2372.
24. Faggioni R., Feingold K.R. and Grunfeld C. (2001). Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J. 15, 2565-2571.
25. Fernandez M., Vizzutti F., Garcia-Pagan J.C., Rodes J. and Bosch J. (2004). Anti-VEGF receptor-2 monoclonal antibody prevents portalsystemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126, 886-894
26. Fernandez M., Mejias M., Angermayr B., Garcia-Pagan J.C., Rodes J. and Bosch J. (2005). Inhibition of VEGF receptor-2 decreases the development hyperdynamic splanchnic circulation and portalsystemic collateral vessels in portal hypertensive rats. J. Hepatol. 43, 98-103.
27. Ferrara N., Gerber H. and LeCouter J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
28. Friedman S.L. (2003). Liver fibrosis: from bench to bedside. J. Hepatol. 38 (Suppl. 1), S38-S53.
29. Friedman S.L. (2004). Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1, 98-105.
30. Friedman S.L. (2008a). Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125-172.
31. Friedman S.L. (2008b). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669.
32. García-Monzón C., Sánchez-Madrid F., García-Buey L., García-Arroyo A., García-Sánchez A. and Moreno-Otero R. (1995). Vascular adhesion molecule expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 108, 231-241.
33. Gaudio E., Barbaro B., Alvaro D., Glaser S., Francis H., Ueno Y., Meininger C.J., Franchitto A., Onori P., Marzioni M., Taffetani S., Fava G., Stoica G., Venter J., Reichenbach R., De Morrow S., Summers R. and Alpini G. (2006). Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 130, 1270-1282.
34. Geerts A. (2001). History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Sem. Liver Dis. 21, 311-335.
35. Grant D.S., Kleinman H.K., Goldberg I.D., Bhargava M.M., Nickoloff B.J., Kinsella J.L., Polverini P. and Rosen EM. Scatter factor induces blood vessel formation in vivo. (1993). Proc. Natl. Acad. Sci. USA 90, 1937-1941.
36. Haraguchi M., Okamura M., Konishi M., Konishi Y., Negoro N., Inoue T., Kanayama Y. and Yoshikawa J. (1997). Anti-angiogenic compound (TNP-470) inhibits mesangial cell proliferation in vitro and in vivo. Kidney Int. 51, 1838-1846.
37. Hellström M., Gerhardt H., Kalén M., Li X., Eriksson U., Wolburg H. and Betsholtz C. (2001). Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153, 543-553.
38. Honda H., Ikejima K., Hirose M., Yoshikawa M., Lang T., Enomoto N. and Sato N. (2002). Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36, 12-21.
39. Huang L. and Li C. (2000). Leptin: a multifunctional hormone. Cell. Res. 10, 81-92.
40. Ikebe T., Yamamoto T., Kubo S., Hirohashi K., Kinoshita H., Kaneda K. and Sakurai M. (1998). Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogen-induced hepatic nodules in rats. Jpn. J. Cancer Res. 89, 143-149.
41. Ikura Y., Morimoto H., Ogami M., Jomura H., Ikeoka N. and Sakurai M. (1997). Expression of platelet-derived growth factor and its receptor in livers of patients with chronic liver disease. J. Gastroenterol. 32, 496-501.
42. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H. and Folkman J. (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature (Lond). 348, 555-557.
43. Ishikawa K., Mochida S., Mashiba S., Inao M., Matsui A., Ikeda H., Ohno A., Shibuya M. and Fujiwara K. (1999). Expressions of vascular endothelial growth factor in non-parenchymal as well as parenchymal cells in rat liver after necrosis. Biochem. Biophys. Res. Commun. 254, 587-593.
44. Jackson C. (2002). Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens. 11, 295-299.
45. Jackson J.R., Seed M.P., Kircher C.H., Willoughby D.A. and Winkler J.D. (1997). The codependence of angiogenesis and chronic inflammation. FASEB J. 11, 457-465.
46. Jain R.K. (2003). Molecular regulation of vessel maturation. Nat. Med. 9, 685-693.
47. Kerbel R.S. (2008). Tumour angiogenesis. New Engl. J. Med. 358, 2039-2050.
48. Kitade M., Yoshiji H., Kojima H., Ikenaka Y., Noguchi R., Kaji K., Yoshii J., Yanase K., Namisaki T., Asada K., Yamazaki M., Tsujimoto T., Akahane T., Uemura M. and Fukui H. (2006). Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 44, 983-991.
49. Koyama H., Nishizawa Y., Hosoi M., Fukumoto S., Kogawa K., Shioi A. and Morii H. (1996). The fumagillin analogue TNP-470 inhibits DNA synthesis of vascular smooth muscle cells stimulated by plateletderived growth factor and insulin-like growth factor-I. Possible involvment of cyclin-dependent kinase 2. Circ. Res. 79, 757-764.
50. Kusaka M., Sudo K., Fujita T., Marui S., Itoh F., Ingber D. and Folkman J. (1991). Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 174, 1070-1076.
51. Lara-Pezzi E., Roche S., Andrisani O.M., Sánchez-Madrid F. and López-Cabrera M. (2001). The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene 20, 3323-3331.
52. Lara-Pezzi E., Gómez-Gaviro M.V., Gálvez B.G., Mira E., Iñiguez M.A., Fresno M., Martínez-A. C., Arroyo A.G. and López-Cabrera M. (2002). The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 andcyclooxygenase-2 expression. J. Clin. Invest. 110, 1831-1838.
53. Leclercq I.A., Farrel G.C., Schriemer R. and Robertson G.R. (2002). Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 37, 206-213.
54. Lee S.J., Semela D., Iredale J. and Shah V.H. (2007). Sinusoidal remodeling and angiogenesis: a new function for the liver specific pericyte? Hepatology 45, 817-825.
55. Luttun A., Dewerchin M., Collen D. and Carmeliet P. (2000). The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia and stroke: insights from genetic studies, Curr. Atheroscler. Rep. 2, 407-416.
56. Majano P., Lara-Pezzi E., López-Cabrera M., Apolinario A., Moreno-Otero R. and García-Monzón C. (2001). Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor kappaB-binding site: evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology 34, 1218-1224.
57. Marra F. (2002). Leptin and liver fibrosis: a matter of fat. Gastroenterology 122, 1529-1532.
58. Mashiba S., Mochida S., Ishikawa K., Inao M., Matsui A., Ohno A., Ikeda H., Nagoshi S., Shibuya M. and Fujiwara K. (1999). Inhibition of hepatic stellate cell contraction during activation in vitro by vascular endothelial growth factor in association with upregulation of FLT tyrosine kinase receptor family, FLT-1. Biochem. Biophys. Res. Commun. 258, 674-678.
59. Matsunaga Y, Terada T. (1999). Peribiliary capillary plexus around interlobular bile ducts in various chronic liver diseases: an immunohistochemical and morphometric study. Pathol. Int. 49, 869-873.
60. Mazzanti R., Messerini L., Monsacchi L., Buzzelli G., Zignego A.L., Foschi M., Monti M., Laffi G., Morbidelli L., Fantappié O., Bartoloni Saint Omer F. and Ziche M. (1997). Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 25, 229-234.
61. Medina J., Caveda L., Sanz-Cameno P., Arroyo A.G., Martín-Vílchez S., Majano P.L., García-Buey L., Sánchez-Madrid F. and Moreno-Otero R. (2003a). Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis Cassociated neoangiogenesis. J. Hepatol. 38, 660-667.
62. Medina J., García-Buey L. and Moreno-Otero R. (2003b). Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment. Pharmacol. Ther. 17, 1-16.
63. Medina J., Arroyo A.G., Sanchez-Madrid F. and Moreno-Otero R. (2004). Angiogenesis in chronic inflammatory liver diseases. Hepatology 39, 1185-1195.
64. Medina J., Sanz-Cameno P., García-Buey L., Martín-Vílchez S., López-Cabrera M. and Moreno-Otero R. (2005). Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. J. Hepatol. 42,124-131.
65. Moon J.-K., Welch T.P., Gonzalez F.J. and Copple B.L. (2009). Reduced Liver Fibrosis in Hypoxia-inducible Factor-1·-Deficient Mice. Am. J. Physiol.-Gastrointest. Liver Physiol. 296, G582-G592.
66. Morales-Ruiz M. and Jimenez W. (2005). Neovascularization, angiogenesis, and vascular remodeling in portal hypertension. In: Portal hypertension: pathobiology, evaluation and treatment. Sanyal A.J. and Shah V.H. (eds). Humana Press. Totowa (NJ). pp 99-112.
67. Morales-Ruiz M., Tugues S., Cejudo-Martin P., Ros J., Melgar-Lesmen P., Fernandez-Llama P., Arroyo V., Rodés J. and Jiménez W. (2005). Ascites from cirrhotic patients induces angiogenesis through the phosphoinositide 3-kinase/Akt signaling pathway. J. Hepatol. 43, 85-91.
68. Novo E. and Parola M. (2008). Redox mechanisms in hepatic chronic wound healing and liver fibrogenesis. Fibrogenesis Tissue Repair 1, 5.
69. Novo E., Cannito S., Zamara E., Valfrè di Bonzo L., Caligiuri A., Cravanzola C., Compagnone A., Colombatto S., Marra F., Pinzani M. and Parola M. (2007). Proangiogenic cytookines as hypoxiadependent factors stimulating migration of human hepatic stellate cells. Am. J. Pathol. 170, 1942-1953.
70. Novo E., Valfrè di Bonzo L.V., Bertolani C., Povero D., Busletta C., Cannito S., Zamara E., Compagnone A., Colombatto S., Marra F., Pinzani M. and Parola M. (2008b). Intracellular redox changes and C-jun N-terminal kinase activation as crucial events in cytokineinduced chemotaxis of human activated hepatic stellate cells. J. Hepatol. 48 (Suppl.2), S184 abstract 484.
71. Okajima A., Miyazawa K., Naitoh Y., Inoue K. and Kitamura N. (1997). Induction of hepatocyte growth factor activator messenger RNA in the liver following tissue injury and acute inflammation. Hepatology 25, 97-102.
72. Okano J., Shiota G. and Kawasaki H. (1999). Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 19, 151-159.
73. Olaso E., Salado C., Egilegor E., Gutierrez V., Santisteban A., Sancho-Bru P., Friedman S.L. and Vidal-Vanaclocha F. (2003). Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 37, 674-685.
74. Parekh S. and Anania F.A. (2007) Abnormal lipid and glucose metabolism in obesity: implications for non-alcoholic fatty liver disease. Gastroenterology 132, 2191-207.
75. Parola M. and Robino G. (2001). Oxidative stress-related molecules and liver fibrosis. J. Hepatol. 35, 297-306.
76. Parola M., Marra F. and Pinzani M. (2008). Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol. Asp. Med. 29, 58-66.
77. Pinzani M. and Marra F. (2001). Cytokine receptor and signalling in hepatic stellate cells. Sem. Liv. Dis. 21, 397-417.
78. Pinzani M. and Rombouts K. (2004). Liver fibrosis-from the bench to clinical targets. Dig. Liver Dis. 36, 231-242.
79. Pinzani M., Gesualdo L., Sabbah G.M. and Abboud H.E. (1989). Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J. Clin. Invest. 84, 1786-1793.
80. Pinzani M., Failli P., Ruocco C., Casini A., Milani S., Baldi E., Giotti A. and Gentilini P. (1992). Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J. Clin. Invest. 90, 642-646.
81. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., Caligiuri A., Pellegrini G., Ngo D.V., Romanelli R.G. and Gentilini P. (1996). Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol. 148, 785-800.
82. Pugh C.W. and Ratcliffe P. (2003). Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 9, 677-684.
83. Rankin E.B. and Giaccia A.J. (2008). The role of hypoxia inducible factors in tumorigenesis. Cell Death Different. 15, 678-685.
84. Rockey D.C. (2001). Hepatic blood flow regulation by stellate cells in normal and injured liver. Sem. Liver Dis. 21, 337-349.
85. Rosmorduc O., Wendum D., Corpechot C., Galy B., Sebbagh N., Raleigh J., Housset C. and Poupon R. (1999). Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary fibrosis. Am. J. Pathol. 155, 1065-1073.
86. Salcedo X., Medina J., Sanz-Cameno P., García-Buey L., Martín-Vilchez S., Borque M., López-Cabrera M. and Moreno-Otero R. (2005). The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 42, 696-701.
87. Saxena N.K., Ikeda K., Rockey D.C., Friedman S.L. and Anania F.A. (2002). Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35, 762-771.
88. Semela D., Das A., Langer D., Kang N., Leof E. and Shah V. (2008). Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function. Gastroenterology 135, 671-679.
89. Semenza G.L. (2001). Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7, 345-350.
90. Semenza G.L. (2004). Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19, 176-182.
91. Shimoda K., Mori M., Shibuta K., Banner B.F. and Barnard GF. (1999). Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int. J. Oncol. 14, 353-359.
92. Shishido T., Yasoshima T., Denno R., Sato N. and Hirata K. (1996). Inhibition of liver metastasis of human gastric carcinoma by angiogenesis inhibitor TNP-470. Jpn. J. Cancer Res. 87, 958-962.
93. Smith J.K., Mamoon M.N. and Duhe R.J. (2004). Emerging roles of targeted small molecule proteine-tyrosine kinase inhibitors in cancer therapy. Oncol. Res. 14, 175-225.
94. Tanaka H., Taniguchi H., Mugitani T., Koishi Y., Masuyama N., Higashida T., Koyama H., Suganuma Y., Miyata K. and Takeuchi K. (1995). Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br. J. Cancer 72, 650-653.
95. Taura K., De Minicis S., Seki E., Hatano E., Iwaisako K., Osterreicher C.H., Kodama Y., Miura K., Ikai I., Uemoto S. and Brenner D.A. (2008). Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 135, 1729-1738.
96. Tilg H. and Hotamisligil G.S. (2006). Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131, 934-945.
97. Tugues S., Fernandez-Varo G., Muñoz-Luque J., Ros J., Arroyo V., Rodés J., Friedman S.L., Carmeliet P., Jiménez W. and Morales-Ruiz M. (2007). Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46, 1919-1926.
98. Van Belle E., Witzenbichler B., Chen D., Silver M., Chang L., Schwall R. and Isner J.M. (1998). Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97, 381-390.
99. Vaupel P., Thews O. and Hoeckel M. (2001). Treatment resistance of solid tumours. Role of hypoxia and anemia. Med. Oncol. 18, 243-259.
100. Wang Y.Q., Ikeda K., Ikebe T., Hirakawa K., Sowa M., Nakatani K., Kawada N. and Kaneda K. (2000). Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 32, 980-989.
101. Wang Y.Q., Luk J.M., Ikeda K., Man K., Chu A.C., Kaneda K. and Fan S.T. (2004). Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem. Biophys. Res. Commun. 317, 358-362.
102. Washington K., Clavien P.A. and Killenberg P. (1997). Peribiliary vascular plexus in primary sclerosing cholangitis and primary biliary cirrhosis. Human Pathol. 28, 791-795.
103. Yancopoulos G.D., Davis S., Gale N., Rudge J., Wiegand S. and Holash J. (2000). Vascular specific growth factors and blood vessel formation. Nature 407, 242-248.
104. Yang S.Q., Lin H.Z., Lane M.D., Clemens M. and Diehl A.M. (1997). Obesity increases sensitivity of endotoxin liver injury: implication for the pathogenesis of steatohepatitis. Procl. Natl. Acad. Sci. USA 94, 2557-2562.
105. Yasoshima M., Tsuneyama K., Harada K., Sasaki M., Gershwin M.E. and Nakanuma Y. (2000). Immunohistochemical analysis of cellmatrix adhesion molecules and their ligands in the portal tracts of primary biliary cirrhosis. J. Pathol. 190, 93-99.
106. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Hicklin D.J., Wu Y., Yanase K., Namisaki T., Yamazaki M., Tsujinoue H., Imazu H., Masaki T. and Fukui H. (2003). Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 52, 1347-1354.